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Abstract
Heart failure is a complex clinical syndrome associated with a significant morbidity and mortality burden. Reductions in left
ventricular (LV) function trigger adaptive mechanisms, leading to structural changes within the LVand the potential development
of dyssynchronous ventricular activation. This is the substrate targeted during cardiac resynchronisation therapy (CRT); however,
around 30–50% of patients do not experience benefit from this treatment. Non-response occurs as a result of pre-implant, peri-
implant and post implant factors but the technical constraints of traditional, transvenous epicardial CRT mean they can be
challenging to overcome. In an effort to improve response, novel alternative methods of CRT delivery have been developed
and of these endocardial pacing, where the LV is stimulated from inside the LV cavity, appears the most promising.
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Abbreviations
AHR Acute haemodynamic response
CMR Cardiac MRI
CRT Cardiac resynchronisation therapy
CS Coronary sinus
ICM Ischaemic cardiomyopathy
LBBB Left bundle branch block
LV Left ventricle
LVEF Left ventricular ejection fraction
LVENDO Left ventricular endocardial
NICM Non-ischaemic cardiomyopathy
QLV The interval between the onset of the QRS
complex on the surface ECG to the first large
positive or negative peak of the LV
electrogram during a cardiac cycle
QRSd QRS duration
RV Right ventricle
Introduction
Heart failure is a complex clinical syndrome associated with a
significant morbidity and mortality burden. Reductions in left
ventricular (LV) function trigger adaptive mechanisms aimed
at regulating the cardiac output; however, over time these
processes cause structural changes within the LV. This remod-
elling can result in the development of dyssynchronous ven-
tricular activation, typically manifested by left bundle branch
block on the 12-lead ECG. This is the substrate targeted dur-
ing cardiac resynchronisation therapy; however, between 30
and 50% of patients do not experience significant benefits
from this treatment [1]. This review will explore the reasons
why some patients fail to respond to traditional transvenous,
epicardial CRT and how novel methods of pacing may offer a
potentially better strategy.
Ventricular remodelling
In response to the progressive haemodynamic stress associat-
ed with heart failure, compensatory structural changes occur
within the heart. The left ventricular myocardial mass and
composition exhibit evidence of change. As this occurs, the
heart becomes less elliptical and more spherical as the geom-
etry and volume of the LV change. This process is called
remodelling and initially enables the heart to increase cardiac
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output by increasing both contractility and stroke volume.
Whilst stroke volume initially increases, this process eventu-
ally becomes deleterious. Progressive enlargement of the ven-
tricle leads to hypertrophy, causing increased wall tension and
ultimately results in the myocardium becoming fibrotic,
impairing contractility. As the left ventricle dilates and re-
models, it exhibits greater contractile dyssynchrony further
reducing efficiency.
Electrical dyssynchrony
Dyssynchronous electrical conduction can manifest as abnor-
mal heart rate modulation, disruption to the sequence of atrio-
ventricular systole and overt ventricular systolic
discoordination which typically manifests as bundle branch
block on the 12-lead ECG. The development of left bundle
branch block is thought to occur as a result of ventricular
remodelling and/or fibrogenic damage to the cardiac condition
system [2]. Progressive increases in the QRS duration herald
deterioration in LV performance [3–6]. Left bundle branch
block results in dyssynchronous ventricular activation causing
an abnormal pattern of mechanical activation and contraction.
In the context of left bundle branch block, the right anterior
septal region is initially activated via the intact right bundle in
juxtaposition to the left basal posterolateral region, which slow-
ly propagates via cell-to-cell, intra-myocardial conduction.
Contraction of the anterior right septum is imbalanced due to
delayed activation of the lateral free wall and occurs unop-
posed. This has the effect of delaying elevation in the intra-
cavity pressure gradient (dP/dtmax) as septal activation merely
results in pre-stretch of the inactive lateral wall.When the lateral
wall finally contracts, the septum is now in diastole, generating
an energy sink which further reduces the overall ejection of
blood via the left ventricular outflow tract. Cardiac mechano-
energetic efficiency is further exacerbated by delayed activation
of the posterolateral papillary muscle, causing sub-optimal clo-
sure of the mitral valve and ultimately mitral regurgitation.
Over time, left bundle branch block (LBBB) activation
causes molecular and cellular remodelling leading to alterations
in glucose uptake, regional perfusion and calcium transport [7].
These factors can be pro-arrhythmic [8] and may help explain
why patients with LBBB and chronic heart failure occasionally
develop acute decompensation without a clear precipitant.
The role of CRT in heart failure management
Cardiac resynchronisation therapy (CRT) aims to eliminate the
dyssynchrony which results from bundle branch block activa-
tion and restore the mechano-energetic efficiency of the heart.
During CRT, both the left and right ventricles are stimulated in
an attempt to re-coordinate cardiac electrical activation and
produce a synchronous and efficient contraction. Several large
randomised controlled trials of biventricular (BiV) pacing have
been conducted which have established the efficacy of this
therapy, which yields both reductions in morbidity and mortal-
ity, see Fig. 1 [9]. As a result of landmark studies, class 1
indications exist for CRT in both European [10] and
American guidelines [11] in patients with symptomatic heart
failure, a severely impaired LV (left ventricular ejection frac-
tion, LVEF <35%) and an ECG demonstrating left bundle
branch block with significant electrical delay.
Response to CRT
Around 30–50% of patients fail to respond to transvenous,
epicardial CRT. This group are classified as non-responders
although no unifying definition of response to CRT exists.
Response can be measured in a variety of different clinical,
functional and structural endpoints and patients can fail to
respond for a variety of different reasons.
The process of defining response to CRT is challenging as
no universally accepted definition of CRT response exists.
Response rates tend to be higher when clinical measures, such
as subjective assessments of symptoms are used but are much
lower when remodelling or outcome measurements are
employed, see Fig. 2.
Additionally, symptomatic improvements do not always
correlate with echocardiographic or functional classification
improvements. There is also no consensus as to the optimal
timeframe to re-assess LV function when gauging remodel-
ling. The most widely accepted definition of response in-
volves an assessment of left ventricular reverse remodelling
(LVRR) 6 months after implantation, with reductions in LV
end-systolic volume (LVESV) the most useful measure [12,
13]. Remodelling endpoints are typically associated with non-
responder rates of between 30 and 45% [14] although in the
systematic review published by Birnie and Tang (2006), the
true figure appears somewhat higher at around 40–50% [15].
Non-response to epicardial CRT
The reasons why some patients fail to adequately respond to
transvenous, epicardial CRT are multifactorial and involve
several pre-, peri- and post implant factors, see Fig. 3.
Pre-implant
Pre-implant factors associated with non-response to CRT in-
clude appropriate patient selection, baseline ECGmorphology
and QRS duration, gender, aetiology, presence of myocardial
scar and disease severity.
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Fig. 2 Rates of non-response to cardiac resynchronization therapy de-
pending on the measure used in controlled trials and large observational
studies of cardiac resynchronization therapy, each represented by a bar.
Event-based measures are shown as blue, remodelling measures as red,
functional and quality of life measures as green, and composite endpoints
as purple bars. Reproduced with permission from [14]. Permission
granted by Oxford University Press
Fig. 1 Results of random-effects
meta-analysis of overall mortality
amongst patients with heart fail-
ure given cardiac
resynchronization therapy plus an
implantable cardioverter defibril-
lator (CRT-ICD) versus an im-
plantable defibrillator (ICD), by
New York Heart Association
(NYHA) class. Values less than
1.0 indicate a decreased risk of
death with cardiac
resynchronization therapy. Note
CI = confidence interval, RR =
relative risk. Reprinted from [9] ©
Canadian Medical Association
(2011). This work is protected by
copyright and the making of this
copy was with the permission of
the Canadian Medical
Association Journal (www.cmaj.
ca) and Access Copyright. Any
alteration of its content or further
copying in any form whatsoever
is strictly prohibited unless
otherwise permitted by law
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Patient selection
Optimal patient selection is critical when looking to maximise
response to CRT. In both European [9] and American [10]
guidelines, CRT is indicated in patients with symptomatic
heart failure who exhibit impaired LV function and display
evidence of ventricular dyssynchrony. Patients must have
been established on optimal tolerated medical therapy and
reversible causes of heart failure should have been excluded,
including ischaemia, arrhythmia or valvular heart disease. In
addition, current patient selection criteria utilise the surface
12-lead ECG to identify electromechanical delay; although
recent sub-group analysis has suggested that the actual pattern
of activation may in fact be more important determinant than
the actual QRS width [16, 17].
ECG morphology and QRS duration
The presence of left bundle branch block morphology is a
strong predictor of response to CRT [18]. Whilst no definitive
data exists evaluating CRT response in patients with right
bundle branch block (RBBB), retrospective analysis suggests
that this group of patients tends to do less well. Interestingly,
when patients with heart failure and RBBB were analysed
using 3D non-contact mapping, they were found to exhibit
significant LVactivation delay in addition to the delay identi-
fied in the RV [19]. In addition, LBBB activation is not ex-
clusively associated with electrical conduction delay [20]. In
one analysis, up to a third of patients with LBBB who
underwent electromechanical or non-contact mapping
demonstrated normal trans-septal activation time and a near-
normal LVendocardial activation time [21]. It is possible that
more nuanced assessments of electrical delay, such as non-
invasive body surface mapping, may be able to detect reme-
diable patterns of electrical delay with greater accuracy.
The evidence for CRT in patients with non-specific intraven-
tricular conduction delay (NICD)who possess a wideQRSwith-
out the appearance of left or right bundle branch block is also
sparse. This ECG abnormality is present in between 3.8 and
5.8% of patients with impaired LV function [22, 23] and can
be caused by a variety of pathophysiological processes, which
may independently influence response. In the context of ischae-
mic heart disease, atypical electrical activation may occur around
an area of necrotic tissue post myocardial infarction, modifying
the appearance of a classic left bundle branch block morphology.
Similarly, in peri-infract block, the trajectory of electrical activa-
tion becomes widened as it bypasses a previously infarcted area.
Finally, NICD can occur in several cardiomyopathic processes as
a result of increased LV myocardial mass and modifications in
myofibrillar organisation.
ConflictingoutcomesfollowingtheuseofCRTinpatientswith
NICD have been reported with some studies appearing to show
benefits in quality of life [24],whilst others revealed no benefit in
clinicalcompositescore, remodellingormortality [16,17,25,26].
Morphology again appears to be the critical determinant with
patients exhibiting a LBBB-like NICD morphology appearing
togain themostbenefit.While reliablycategorising the activation
pattern on the basis of a 12-lead ECG alone can be challenging,
this is possible using both invasive electroanatomicalmapping or
novel non-invasive body surfacemapping technology.
Fig. 3 Factors associated with
sub-optimal CRT response.
Reproduced with permission
from Wilfried Mullens and Petra
Nijst. Understanding non-
response to cardiac
resynchronisation therapy; com-
mon problems and potential solu-
tions. Journal of the American
College of Cardiology. 2017
69(17):2130–2133
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Gender
Women have been consistently under-represented in nearly all
large-scale trials of CRT and yet gender appears to play a key
part in determining response to CRT [27–30]. Female CRT
recipients appear to achieve superior survival benefits when
compared to male recipients, although lower rates of ischae-
mic cardiomyopathy (ICM) confound this analysis [28, 30].
Interestingly, it appears that the degree of electrical
dyssynchrony required to predict response to CRT differs be-
tween the sexes. The analysis by Varma et al. identified that
the peak probability of response occurred with a comparative-
ly narrower QRS than that of men [31]. Whilst the class 1
indication for CRT of a QRS > 150 ms affords men a ~60%
chance of responding to CRT, women achieved the same level
of response with a QRS of just 130 ms, see Fig. 4.
Aetiology and myocardial scar
In roughly 50% of patients receiving CRT, the aetiology of
their heart failure will be ischaemic in origin [14]; however,
ischaemic aetiology is an independent predictor of non-
response to CRT [32, 33]. Other studies have shown that pa-
tients with ICM experience have less improvement in LVEF
than patients with non-ischaemic, dilated cardiomyopathy
(DCM) [34, 35]. The difference in remodelling has been at-
tributed to a sequelae of the greater burden of scarred
myocardium typically identified in ischaemic patients, reduc-
ing the potential for LV remodelling [36].
Atrial fibrillation
Around 25% of patients undergoing CRT implantation are in
permanent atrial fibrillation (AF) [37]. It is common for pa-
tients with AF to concurrently exhibit older age, increased
severity of heart failure and additional comorbidities than pa-
tients who present with sinus rhythm. Patients with AF are
more likely to have a faster and more irregular heart than
patients in sinus rhythm, and the aetiology of their LV dys-
func t ion may in some ins tances be a resu l t o f
tachycardiomyopathy. When the presenting rhythm was
analysed in a randomised trial, CRT appeared to confer no
benefit to patients with coexistent AF, whilst a 25% reduction
in mortality was observed amongst those in sinus rhythm [38].
One explanation for this discrepancy is that amongst the group
with AF, only 50% of the patients experienced a BiV pacing
burden in excess of 90%. As such, the current European
guidelines include the caveat that when contemplating CRT
implantation in patients with AF, a class IIa indication exists,
Bprovided that a BiV pacing as close to 100% as possible can
be achieved^ [10].
Given the importance of maximising the percentage of BiV
pacing, it has been postulated that all patients with AF should
undergo atrio-ventricular (AV) junctional ablation and this
Fig. 4 Probability of CRT response according to QRS duration
(QRSd) as a continuous function. Parametric model: multivariable
logistic regression shown with the corresponding 68% confidence
limits (comparable to ± 1 SD). The decile points representing mean
percentage of responders according to the deciles of QRSd are given
as a crude verification of model fit. a Overall. Closed symbols repre-
sent decile points based on the equal number of patients (17 or 18
patients). b Gender-specific plot is based on a patient with baseline
LVEDD 6 cm, baseline LVEF 20%, and 2 years from implant to
follow- up echocardiography. Each decile point represents an average
of ~ 10 patients (closed symbols: women; open symbols: men).
Shapes were confirmed by semi- and nonparametric modelling.
Reproduced with permission from [31]
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approach does appear to enhance the effects of CRT with the
samemagnitude as those seen in patients with sinus rhythm [39].
Upgrades to CRT
Patients with a bradycardia pacing system in situ who go on to
develop heart failure symptoms account for around 23–28%
of CRT implants. The deleterious effects of chronic RV pacing
have been well established [40–42] and recently reviewed
[43]. As such, implantation of a BiV pacing system may be
appropriate for patients with evidence of symptomatic heart
failure and reduced ejection fraction who are expected to ex-
perience a high pacing burden. It is likely stricter adherence to
professional practice guidelines identifying suitable patients to
undergo an upgrade to a CRT system will improve the re-
sponse rate to the therapy.
Peri-implant
Peri-implant factors associated with non-response to CRT in-
clude utilising appropriate LV lead technology and optimisa-
tion of the LV lead stimulation site.
LV lead technology
Transvenous, epicardial CRT was traditionally performed by
implanting a bipolar pacing lead in a tributary of the coronary
sinus, facilitating depolarisation of the LV. Multisite pacing
(MSP) where stimulation is delivered from two or more sites
within the LV would intuitively appear preferable to single-
site stimulation. In early pilot work, MSP was associated with
greater reverse remodelling [44, 45]; however, in a larger,
randomised study of prior non-responders to CRT, no clinical
or echocardiographic benefit was observed [46].
MSP can also be delivered via multipoint pacing (MPP).
This technique utilises quadripolar LV pacing leads which
have four integrated pacing cathodes along the course of the
lead, allowing greater customisation from any of the of the
10–17 MPP vectors available. The increased choice for the
implanting physician means it is possible to programme
around frequently occurring issues including high pacing
thresholds–potentially caused by areas of scar- or phrenic
nerve stimulation, where LV depolarisation causes diaphrag-
matic twitching. The use of MPP has been shown to yield
greater improvements in acute haemodynamic response [47]
and in a small, randomised study, greater improvements in
overall response [48].
Stimulation site
The optimal LV pacing site displays large inter and intra-
patient variability amongst patients with both DCM [49] and
ICM [50–52]. Delivering stimulation from a more apical
position has largely been shown to yield less favourable out-
comes [53, 54], and this practice is not endorsed in current
guidelines [10]. In general, there is a consensus that the lateral
free wall represents the most favourable target for LV lead
deployment, typically within the lateral or postero-lateral car-
diac veins of the coronary sinus [55–58]. Unfortunately, the
constraints of the coronary sinus anatomy mean it is occasion-
ally impossible to even implant an LV lead, let alone target a
specific site which displays desirable viability and latency
[59].
Post implant
Post implant factors associated with non-response to CRT
include remote monitoring, frequency of biventricular pacing,
device programming and optimisation.
Remote monitoring
Almost all modern cardiac implanted electronic devices
(CIEDs) have the capability to allow remote device follow
up. Large, randomised studies have consistently shown that
remote device monitoring is both feasible and reduces the
need for ambulatory outpatient clinic attendance [60]. The
use of remote monitoring has been shown to improve clinical
outcomes for patients with heart failure as well as achieving a
significant reduction in mortality [61]. However, similar ben-
efits were not observed when a more rationalised approach to
remote monitoring was adopted in other work [62].
Whilst CIEDs can analyse fluid status by calculating tho-
racic impedance as part of a multiparametric assessment,
monitoring-only implantable technologies have also been de-
vised. The CardioMEMS Heart Failure system (Abbott
Medical Inc., Atlanta, GA, USA) is a wireless pulmonary
artery haemodynamic monitor, which provides an accurate
assessment of real time pulmonary artery (PA) pressure,
allowing the physician to optimise pharmacotherapy. Use of
this system was associated with a 33% reduction in
hospitalisations when compared to standard of care [63].
Such systems appear to hold a great deal of promise, particu-
larly if they could be integrated with the currently available
CIED multiparametric assessments.
Biventricular pacing burden
In order for a CRTsystem to function effectively, it is essential
that it is able to deliver consistent biventricular pacing.
Frequent ventricular ectopics and atrial tachyarrhythmias can
reduce the frequency of biventricular pacing and were identi-
fied in up to a third of non-responders to CRT [64]. There are
several mechanisms by which atrial tachyarrhythmias reduce
response to CRT. Rapid atrial rates can result in loss of ven-
tricular stimulation, but of equal significance are the
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detrimental haemodynamic sequelae of the irregularity of the
rhythm as well as the loss of intrinsic atrial function. A strat-
egy of attempting to maintain sinus rhythm using pharmaco-
logical therapy in patients with heart failure conferred no ben-
efit over a strategy of rate control [65]. Other strategies to
increase the frequency of biventricular pacing include both
catheter ablation [66, 67]. Recent work has suggested that this
approach may even confer a survival benefit in patients with
AF and heart failure [68]. AV junction ablation is an alterna-
tive strategy in patients with AF and whilst rendering the
patient pacing dependant, appears highly effective when com-
bined with biventricular pacing. As such, this practice is en-
dorsed in the most recent guidelines [10].
Ventricular extra systolic beats can similarly disrupt the
efficient function of a CRT system, reducing the frequency
of effective biventricular pacing and as such, contributing to
non-response. Again, the therapeutic target is to minimise the
occurrence of such events either through the use of pharma-
cological therapy or catheter ablation [69].
Programming and optimisation
Appropriate programming can increase the frequency of
biventricular pacing but is also essential in order to ensure
the optimal mechanical functioning of the heart, which facil-
itates greater response. Arguably, the most important settings
requiring optimisation are the pacing mode, upper and lower
rate limits, the LV capture voltage, the stimulation vector and
A-V and V-V intervals. Programming a high upper tracking
rate ensures biventricular pacing is maintained during exer-
cise. Similarly, the LV pacing output should include an ade-
quate safety margin to ensure continual BiV pacing, although
some modern devices can automatically adjust this parameter.
Iterative optimisation of the A-V and V-V intervals using
doppler echocardiography is the established reference method
of achieving optimal programming by ensuring optimal dia-
stolic filling of the LV [70, 71]. Recent large multicentre stud-
ies evaluating this practice have shown it to be largely inef-
fective when compared to the use of empirical programming
[72, 73]. A more promising technique, which optimises the A-
V and V-V intervals using an integrated haemodynamic sen-
sor, is currently undergoing further assessment [74].
Biventricular endocardial pacing
The persistent rate of non-response to transvenous, epicardial
CRT has led to the development of novel forms of undertaking
CRT. Of these, biventricular endocardial pacing (BiV ENDO),
where LV stimulation occurs from within the LV cavity, holds
a great deal of promise. This technique is associated with
several advantages over epicardial activation. BiV ENDO
pacing can be achieved using several different approaches
including the use of novel, leadless pacing.
Benefits of biventricular endocardial pacing
A large body of evidence exists highlighting the potential
benefits of BiV ENDO CRT.
Access to sites
Failure to implant an LV lead in a tributary of the coronary sinus
during a transvenous, epicardial CRT procedure occurs in
around 5–15% of cases [55, 75, 76]. Improvements in delivery
kit [77] in conjunction with greater operator experience and the
widespread adoption of quadripolar pacing leads [78] mean that
in amore recent series, failure to implant an LV lead now occurs
in under 5% of cases [79]. This can occur due to difficulty
cannulating the coronary sinus ostium or passing the LV lead
into a CS branch, unsatisfactory pacing parameters or phrenic
nerve stimulation associated with LV pacing. Where LV lead
implantation is feasible, it is confined to the available anatomy
of the CS. Consequently, the final lead position is dependent on
the presence of a suitable target vein and when none exists, it
may be necessary to accept a sub-optimal position. In addition,
around 26% of patients undergoing an upgrade procedure from
a pre-existing bradycardia pacing system may have central ve-
nous stenoses preventing the implantation of a transvenous LV
lead [80]. In this population, it can prove impossible to implant
an LV lead in 20–50% of patients [81, 82].
BiV ENDO pacing is not reliant on the CS anatomy and
instead, operators can choose to deliver stimulation at any site
within the LV cavity. This allows for customisation of the
stimulation site based on the patient’s pathology and physiol-
ogy. In addition, whilst lead-based pacing systems may still
encounter issues such as central venous stenosis and occlu-
sion, particularly in the upgrade population, newer wireless
pacing systems which can be delivered via a retrograde aortic
approach eliminate the need for central venous access [83].
Phrenic nerve stimulation and activation threshold
Clinically relevant phrenic nerve stimulation (PNS) can com-
plicate LV lead deployment during transvenous, epicardial
CRT implantation and this complication is encountered in
over 20% of patients at implant or at follow up [84].
Unfortunately, the likelihood of encountering PNS increases
when the lead is deployed at sites most associated LV reverse
remodelling. Reducing the LV pacing output is a recognised
technique for overcoming PNS and it is important to note that
endocardial capture thresholds appear lower than equivalent
parameters observed during BiV EPI [85]. In addition, if PNS
is encountered during implantation of a BiV ENDO pacing
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system, the operator has the freedom of the entire LV cavity to
select an alternative pacing site.
Activation velocity
Endocardial stimulation of the LV facilitates more rapid myo-
cardial depolarisation as wave front propagation occurs along
the shorter endocardial surface of the heart. Several studies
have also demonstrated enhanced conduction velocities asso-
ciated with stimulation of endocardial tissue [86–88]. One
hypothesis for this more rapid activation is the earlier recruit-
ment of fast conducting Purkinje fibres with the capability of
quickly disseminating activation. However, Purkinje fibres
are largely electrically isolated from the surrounding myocar-
dial tissue and require direct fibre stimulation [89].
Additionally, given the Purkinje fibres form a loose network
within the LVendocardium, other factors are thought to play a
more central role.
Hyde et al. set out to establish a greater understanding of
fast endocardial conduction (FEC). Non-Purkinje sub-endo-
cardial tissue conducts impulses faster than either mid-
myocardial or epicardial fibres [89]. Instead, fibre orientation
and anisotropy appear critical [87, 90] in addition to higher
gap junction [91] and sodium channel [92] density and in-
creased cell area at the endocardium [93].
Arrhythmogenesis
Traditional CRT delivers electrical stimulation to the epicardial
surface of the LV wall. This pattern of activation is juxtaposed
to the sequence exhibited during intrinsic myocardial activation
which follows an endocardial to epicardial course. Reversing
the normal depolarisation sequence is thought to promote
repolarisation heterogeneity, which can prolong the QTc inter-
val in susceptible patients and result in malignant arrhythmias
[94–97]. In contrast, BiV ENDO pacing was associated with a
reductions in both QT dispersion and T peak to end, two im-
portant markers of dispersion of repolarisation [98].
Improving response through endocardial pacing
Increasingevidence supports thehypothesis thatBiVENDOpac-
ing has the capability to achieve greater electrical
resynchronisation and consequently, maximise response to CRT.
Traditionally,BiVENDOpacinghasbeenperformedinarelative-
ly small number of patients, typically thosewith failure to achieve
conventional CRT or those that have been non-responders. The
recentlypublishedALSYNCstudywas the firstmulticentre study
of LV endocardial pacing and demonstrated the feasibility and
safety of LVendocardial CRT delivered through the atrial trans-
septal approach [99]. In 138patientswith either prior sub-optimal
response to conventional CRT, failure of LV lead implantation or
sub-optimal coronaryvenous anatomy, the investigators achieved
ahighimplantsuccess rate (89.4%),withstablepacingparameters
and an 82.2% freedom from complications at 6 months.
Furthermore, clinical and echocardiographic improvement was
59 and 55% respectively in a groupwith prior non-response, sug-
gestingthatLVendocardialpacingmayovercometheissueofpoor
response toepicardialCRT.These figuresare reinforcedbya large
meta-analysis of BiV ENDOwhich confirmed a meta-analytical
echocardiographic response rate of 63.3% [100].
The acute haemodynamic benefits of BiV ENDO appear
superior to those achievable utilising BiV EPI, even amongst a
cohort of ischaemic, non-responders to conventional epicardi-
al CRT [101]. When a direct comparison between BiV ENDO
and BiV EPI was performed, the optimal endocardial location
appeared superior to the optimal epicardial pacing site.
However, the location of the optimal site was different in each
patient and a sub-optimal endocardial location could be in fact
prove detrimental to cardiac function. As such, if endocardial
CRT is to be widely adopted, it is likely that tailoring the LV
lead location to the individual patient’s anatomy, physiology
and pathology will be required.
Biventricular endocardial pacing systems
Lead-based pacing systems
Chronic BiV ENDO CRT has traditionally been delivered via
a pacing lead delivered via either a transventricular-septal or
atrial-septal puncture. Due to the risk of thrombus formation
resulting in systemic embolization, lead-based LVendocardial
pacing requires lifelong anti-coagulation. In a recent meta-
analysis, the stroke rate was found to be 2.5 per 100 patient
years [100]. Often, these events were attributed to periods of
reduced anti-coagulation given the difficulty associated with
maintaining a therapeutic INR.
Following a trans-septal implant, the potential also exists
for an adverse interaction between the mitral valve and an LV
lead which passes through it. The presence of a pacing lead
can worsen valvular regurgitation and this phenomenon has
been acknowledged with right-sided leads. Reassuringly in
the largest series of trans-septal LVendocardial pacing to date,
no system-related valvular complications were recorded.
Instead, echocardiography showed reductions in mitral regur-
gitation as a result of improved LV function [99]. The other
major concern is the increased risk ofmitral valve endocarditis
should the system become infected. Secondary infectious foci
including both cerebral and renal abscess formation are asso-
ciated with the systemic embolization of vegetations.
Atrial trans-septal
Lead-based BiV ENDO is predominantly delivered via the
atrial trans-septal approach [102]. Superior and inferior access
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is frequently required in order to puncture the atrial septum
and successfully position the lead in the LV although several
refinements of this procedure have been described.
Ventricular trans-septal
Ventricular trans-septal techniques allow the deployment of
the lead using only superior access, eliminating the need for
femoral punctures [103]. This approach may be associated
with both a lower risk of stroke and disruption to mitral valve
function by eliminating the presence of pacing leads in the left
atrium crossing the mitral valve, although a target INR of 2.5–
3 is still recommended [103].
Apical trans-septal
Ahybrid surgical/percutaneous approach has also been described
where the LVapex is accessed via amini-thoracotomy facilitating
the deployment of a lead at the LVapex, which is then tunnelled
up to a generator, implanted in the conventional sub-clavicular
position [104]. Whilst the results from this series of 20 patients
appear promising, this is a more invasive option and a higher
target INR of 3–3.5 is recommended.
Leadless pacing systems
Whilst chronic BiV ENDO delivered via a pacing lead cur-
rently requires ongoing anti-coagulants due to the risk of
thrombus formation, newer wireless technology almost entire-
ly eliminated this risk. Formal anti-coagulation is not required
and this development increases the likelihood of endocardial
pacing becoming more widespread.
Transarterial leadless LV endocardial pacing
A leadless BiV ENDO CRT pacing system has been devel-
oped, which eliminates the need for any form of pacing lead to
be present within the left ventricle. Instead stimulation is de-
livered to the endocardial surface of the heart acoustically
from an ultrasound (USS) pulse generator, implanted subcu-
taneously in an intercostal space, see Fig. 5. The USS waves
stimulate a small receiver-electrode which is deployed percu-
taneously via the femoral artery, into the LV cavity. Acoustic
USS energy is converted to an electronic pacing pulse by the
receiver electrode. The pulse generator is triggered by RV
pacing, resulting in near simultaneous (within 3 ms) LV and
RVendocardial activation.
Fig. 5 The WiSE CRTwireless
biventricular endocardial pacing
system. Reproduced with
permission from EBR Systems,
Sunnyvale, California, USA
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Whilst co-axial alignment of the USS pulse generator and
pacing electrode is desirable, the USS transmitter uses beam-
forming to direct the energy towards the pacing electrode,
minimising the amount of energy required. Refinements of
this generator mean it can now be implanted via a small hor-
izontal incision and is attached to a dedicated battery, typically
placed in the mid-axillary line via traditional lead tunnelling
techniques. Battery life of the current system is typically quot-
ed at 3 years, but newer battery technology currently nearing
release is expected to double this longevity to over 6 years.
Early clinical studies evaluating this system confirmed im-
plantation was safe and capable of achieving consistent
biventricular capture [83] whilst more recent work has shown
the system to be highly efficacious and associated with a clin-
ical response rate of 84.8% [105].
Transvenous leadless LV endocardial pacing
The most commonly encountered complication associated
with the use of theWiSE CRTsystem is femoral arterial access
complications. In addition, not every patient has suitable anat-
omy to allow sufficient arterial access to allow the insertion of
the electrode delivery catheter. Ischaemic heart disease is com-
mon in this population and as such, concurrent peripheral
vascular disease is frequently encountered.
A method of transvenously accessing the LV cavity via an
atrial trans-septal puncture has been described to facilitate
deployment of the pacing electrode [106]. WiSE CRT implan-
tation is commonly performed by electrophysiologists who
are typically more comfortable obtaining trans-septal access
thanmanagingwide bore arterial access and as such, this route
holds a great deal of promise. Early series evaluating its use
have confirmed the safety of this approach [107].
Conclusion
Non-response to CRT is a multifactorial issue. Improving pa-
tient selection and post implant device troubleshooting remain
the cornerstone of optimising patient outcomes. Whilst newer
lead technology including multipoint pacing and a greater
focus on the importance of site selection are likely to be ben-
eficial, the limitations of transvenous, epicardial CRT are
widely acknowledged. In patients where implanting a
transvenous lead is not possible, consideration should be giv-
en to endocardial pacing. Newer leadless LVendocardial sys-
tems no longer mandate lifelong anti-coagulation. In addition,
endocardial pacing appears capable of yielding more effective
electromechanical resynchronisation. Given the ability to
stimulate the LV from any location, this technique would ap-
pear to offer a significant benefit to patients where
transvenous lead implantation is restricted to inferior sites.
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